Vol.18 No.3

Case Report

Treatment of retinal vasculitis in Behçet’s disease with rituximab

Authors

Shahram Sadreddini1 , Hamid Noshad1 , Mahshid Molaeefard2 , Rahim Noshad3

  • Tabriz University of Medical Sciences, Golgasht St., 51664, Tabriz, Iran
  • Tehran University of Medical Sciences, Enghelab, Tehran, Iran
  • Alavi Hospital, Tabriz University of Medical Sciences, 522 Military Hospital, Tabriz, Iran
Received:

12 October 2007

Accepted:

24 January 2008

Published online:

26 April 2008

Full Text

PDF　(member's only)

Abstract

Behçet’s disease (BD) is more common in eastern than western countries. Physicians have frequently encountered problems in its treatment, especially eye involvement. Recurrent oral and genital aphthous ulcerations are the hallmarks of Behçet’s disease but other organs can be involved and ocular disease is one of the most disabling manifestations. Up to now, there are some problems in treatment of the retinal vasculitis due to Behçet’s disease. We reported one patient, with visual loss due to retinal vasculitis that was resistant to prednisolone and azathioprine. Our patient was treated successfully with rituximab and his remission was sustained for 24 months of follow-up. Rituximab is a chimeric monoclonal antibody that acts against the specific B cell antigen, CD20. The recent success of rituximab in autoimmune diseases, which is considered to be T cell-mediated, indicates that B cells must have a much broader role in the pathogenesis of autoimmune diseases than generally appreciated.

Key words

Rituximab - Behçet’s disease - Retinal vasculitis